AMGN241018C255000
- 61.40
- 0.000.00%
Amgen Newsroom
Dow Drops 138 Points On Losses For Shares Of American Express, Merck
Express News | Amgen Says FDA Shifted the Pdufa Date by 3 Months to Jan 17, 2025 to Allow Additional Time for Review of Supplemental Data Recently Submitted to Agency
Express News | Amgen Says FDA Has Extended Review Period for Lumakras in Combination With Vectibix for Treating Some Colorectal Cancer Patients
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Bernstein initiates coverage on eli lilly and co, gilead sciences, and amgen with an "outperform" rating. Bernstein stated that the bullish ratings on gilead and amgen are based on optimistic expectations for revenue growth from key assets from now until 2030, including gilead's HIV PreEP treatment lenacapavir, amgen's weight loss drug MariTide, and rare disease investment portfolio. As for eli lilly and co, Bernstein stated that the rating "depends on how it uses the cash generated from weight loss drugs", eli lilly and co is ready to leverage a diversified investment portfolio and drive growth through weight loss drugs. In addition, Bern
Looking Into Amgen's Recent Short Interest
Express News | Amgen Inc : Bernstein Initiates Coverage With Outperform Rating; Target Price $380
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating
FedEx and 5 Other Stocks on Track to Raise Dividends by More Than 6%
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Bernstein begins coverage of eli lilly and co (LLY.US), gilead sciences (GILD.US), and amgen (AMGN.US), all rated as "outperforming large cap".
Lilly, Gilead, Amgen Started at Outperform by Bernstein
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $381
Amgen Says Phase 3 Uplizna Trial in Generalized Myasthenia Gravis Meets Primary Endpoint
Express News | Amgen Presents Positive Phase 3 Data for Uplizna® (Inebilizumab-Cdon) in Generalized Myasthenia Gravis (Gmg) at Aanem 2024
DBS Maintains Amgen(AMGN.US) With Buy Rating
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Remains a Buy on Amgen (AMGN)
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Amgen Seeing Muted Upside Potential for Drug Pipeline, Truist Says